1Klein R,Klein BE.Epidemiology of eye diseases in diabetes[M].In:Flynn HW Jr,Smiddy WE,eds.Diabetes and Ocular Diseases.San Francisco:American Academy of Ophthalmology;2000:19-67.
2李凤鸣.眼科全书[M].北京：人民卫生出版社,1996.2575.
3Van Heyningen R.Formation of polyols by the lens of the rat with sugar cataract[J].Nature,1959,184:194-195.
4Crabbe MJ,Goode D.Aldose reductase:a window to the treatment of diabetic complications[J]?Prog Retin Eye Res,1998,17(3):313-383.
5Nicolucci A,Carinci F,Graepel JG,et al.The efficacy of to1erstat in the treatment of diabetic peripheral neuropathy.A meta-analysis of individual patient data[J].Diabetes Care,1996,19(10):1902-1906.
7van Gerven JM,Boot JP,Lemkes HH,et al.Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial[J].Doc Ophthalmol,1994,87(4):355-365.
8Tromp A,Hooymans JM,Barendsen BC,et al.The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy[J].Documenta Ophthalmologica,1991,78(3-4):153-159.
9Hogeboom vBI,Polak BC,Reitchert-Thoen JW,et al.Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy[J].Diabetologia,2002,45:203-209.
10Aiello LP,Bursell SE,Clermont A,et al.Vascular endothelial growth facor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor[J].Diabetes,1997,46(9):1473-1480.
